Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma
Author:
Funder
Japan Society for the Promotion of Science
Juntendo University
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine
Reference53 articles.
1. Chimeric antigen receptor therapy;June;N. Engl. J. Med.,2018
2. The principles of engineering immune cells to treat cancer;Lim;Cell,2017
3. Engineering strategies to overcome the current roadblocks in CAR T cell therapy;Rafiq;Nat. Rev. Clin. Oncol.,2020
4. Driving CAR T-cells forward;Jackson;Nat. Rev. Clin. Oncol.,2016
5. Chimeric antigen receptor T-cell therapies for lymphoma;Brudno;Nat. Rev. Clin. Oncol.,2018
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis;Experimental Hematology;2024-02
2. Immune Cell Generation from Human-Induced Pluripotent Stem Cells: Current Status and Challenges;Advances in Pluripotent Stem Cells;2024-01-31
3. Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation;Frontiers in Immunology;2024-01-12
4. iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer;Cell Reports Medicine;2023-12
5. Engineered hematopoietic and immune cells derived from human pluripotent stem cells;Experimental Hematology;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3